CML patients treated with dasatinib presented more classical NK cells (CD3−CD56+) and matured NK cells (CD56+CD57+) compared to imatinib- or nilotinib-treated patients [38]. Here, B3GAT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.